January 30, 2019
Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers
Read More
January 30, 2019
Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers
Read More
January 30, 2019
Savolitinib vs. Sunitinib in MET-driven PRCC
Read More
January 30, 2019
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Read More
January 30, 2019
A Study to Assess the Immunogenicity and Safety of GSK Biologicals’ Infanrix® -IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
Read More
January 30, 2019
A Study to Assess the Immunogenicity and Safety of GSK Biologicals’ Infanrix® -IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
Read More
January 30, 2019
Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children
Read More
January 30, 2019
Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children
Read More
January 30, 2019
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants
Read More
January 30, 2019
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants
Read More
December 10, 2018
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
Read More
December 10, 2018
Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals’ Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects
Read More
Load More
X